{"id": "article-85736_0", "title": "Ropinirole -- Continuing Education Activity", "content": "Ropinirole is a drug that targets D2 receptors to manage Parkinson disease (PD) and restless leg syndrome. As a dopamine agonist, it acts on G-protein-coupled inhibitory neurons, inhibiting adenylyl cyclase and calcium\u00a0channels while activating potassium channels. This mechanism maximizes the \"on\" time and minimizes the \"off\" time associated with disease progression, making ropinirole an attractive option for\u00a0managing early and advanced-stage PD. Beyond its primary indications, ropinirole has also proved effective in addressing sleep disturbances and nocturnal symptoms linked to PD. This activity explores the applications of ropinirole and discusses its indications, contraindications, mechanism of action, adverse events, and essential considerations\u00a0when using it as a therapy component.", "contents": "Ropinirole -- Continuing Education Activity. Ropinirole is a drug that targets D2 receptors to manage Parkinson disease (PD) and restless leg syndrome. As a dopamine agonist, it acts on G-protein-coupled inhibitory neurons, inhibiting adenylyl cyclase and calcium\u00a0channels while activating potassium channels. This mechanism maximizes the \"on\" time and minimizes the \"off\" time associated with disease progression, making ropinirole an attractive option for\u00a0managing early and advanced-stage PD. Beyond its primary indications, ropinirole has also proved effective in addressing sleep disturbances and nocturnal symptoms linked to PD. This activity explores the applications of ropinirole and discusses its indications, contraindications, mechanism of action, adverse events, and essential considerations\u00a0when using it as a therapy component."}
{"id": "article-85736_1", "title": "Ropinirole -- Continuing Education Activity", "content": "Objectives: Identify the approved indications for ropinirole therapy. Recognize the possible adverse effects of ropinirole. Screen patients for ropinirole therapy based on its contraindications. Implement coordinated\u00a0care between members of the interprofessional team when using ropinirole therapy. Access free multiple choice questions on this topic.", "contents": "Ropinirole -- Continuing Education Activity. Objectives: Identify the approved indications for ropinirole therapy. Recognize the possible adverse effects of ropinirole. Screen patients for ropinirole therapy based on its contraindications. Implement coordinated\u00a0care between members of the interprofessional team when using ropinirole therapy. Access free multiple choice questions on this topic."}
{"id": "article-85736_2", "title": "Ropinirole -- Indications", "content": "Dopamine agonists are drugs used to treat various central nervous system disorders. Ergoline (eg, bromocriptine) and non-ergoline dopamine agonists (eg, ropinirole, pramipexole) are useful\u00a0in treating Parkinson disease (PD). Ropinirole is a US Food and Drug Administration-approved medication indicated for treating restless legs syndrome (RLS) and PD. The drug acts by selectively binding to D2 receptors.\u00a0Ropinirole treats both early and advanced-stage Parkinson disease and can\u00a0maximize the \"on\" time and minimize the \"off\" time of the disease.\u00a0Ropinirole is also helpful in managing sleep disturbances and nocturnal\u00a0symptoms\u00a0associated with Parkinson disease. [1] [2] [3]", "contents": "Ropinirole -- Indications. Dopamine agonists are drugs used to treat various central nervous system disorders. Ergoline (eg, bromocriptine) and non-ergoline dopamine agonists (eg, ropinirole, pramipexole) are useful\u00a0in treating Parkinson disease (PD). Ropinirole is a US Food and Drug Administration-approved medication indicated for treating restless legs syndrome (RLS) and PD. The drug acts by selectively binding to D2 receptors.\u00a0Ropinirole treats both early and advanced-stage Parkinson disease and can\u00a0maximize the \"on\" time and minimize the \"off\" time of the disease.\u00a0Ropinirole is also helpful in managing sleep disturbances and nocturnal\u00a0symptoms\u00a0associated with Parkinson disease. [1] [2] [3]"}
{"id": "article-85736_3", "title": "Ropinirole -- Indications -- Parkinson Disease", "content": "Parkinson disease (PD) is a condition characterized by the loss of dopamine receptors in the substantia nigra pars compacta leading to cognitive and motor decline. Rigidity, tremors, and bradykinesia are\u00a0common\u00a0features of this disease. [4] There are periods when these patients demonstrate good motor function, referred to as 'on' time, and\u00a0periods of\u00a0severe motor decline, referred to as 'off' time. Ropinirole is equally effective in treating PD as monotherapy or in combination with other medications like L-dopa. [5] According to the American Academy of Neurology guidelines, clinicians\u00a0should prescribe the lowest dose of\u00a0dopamine agonist like ropinirole for motor symptoms in early PD. [6]", "contents": "Ropinirole -- Indications -- Parkinson Disease. Parkinson disease (PD) is a condition characterized by the loss of dopamine receptors in the substantia nigra pars compacta leading to cognitive and motor decline. Rigidity, tremors, and bradykinesia are\u00a0common\u00a0features of this disease. [4] There are periods when these patients demonstrate good motor function, referred to as 'on' time, and\u00a0periods of\u00a0severe motor decline, referred to as 'off' time. Ropinirole is equally effective in treating PD as monotherapy or in combination with other medications like L-dopa. [5] According to the American Academy of Neurology guidelines, clinicians\u00a0should prescribe the lowest dose of\u00a0dopamine agonist like ropinirole for motor symptoms in early PD. [6]"}
{"id": "article-85736_4", "title": "Ropinirole -- Indications -- Restless Leg Syndrome", "content": "Restless leg syndrome (RLS), also known as Willis-Ekbom disease, is the uncontrollable urge to move the legs\u00a0to resolve a sensation commonly described as burning, painful, or tingling. [7] Ropinirole also treats moderate to severe RLS; relief can occur within\u00a02 days of initiating treatment. [8] The American Academy of Sleep Medicine (AASM) endorses using dopamine agonists like ropinirole to manage moderate-to-severe RLS. [9]", "contents": "Ropinirole -- Indications -- Restless Leg Syndrome. Restless leg syndrome (RLS), also known as Willis-Ekbom disease, is the uncontrollable urge to move the legs\u00a0to resolve a sensation commonly described as burning, painful, or tingling. [7] Ropinirole also treats moderate to severe RLS; relief can occur within\u00a02 days of initiating treatment. [8] The American Academy of Sleep Medicine (AASM) endorses using dopamine agonists like ropinirole to manage moderate-to-severe RLS. [9]"}
{"id": "article-85736_5", "title": "Ropinirole -- Mechanism of Action", "content": "Ropinirole has a high affinity for post-synaptic dopamine receptors in the central and peripheral nervous systems. The dopamine receptors (D2) are G-protein-coupled inhibitory neurons located\u00a0primarily in the striatonigral, mesolimbic, and tuberoinfundibular systems. They inhibit adenylyl cyclase and calcium\u00a0channels and activate potassium channels. [10] [11]", "contents": "Ropinirole -- Mechanism of Action. Ropinirole has a high affinity for post-synaptic dopamine receptors in the central and peripheral nervous systems. The dopamine receptors (D2) are G-protein-coupled inhibitory neurons located\u00a0primarily in the striatonigral, mesolimbic, and tuberoinfundibular systems. They inhibit adenylyl cyclase and calcium\u00a0channels and activate potassium channels. [10] [11]"}
{"id": "article-85736_6", "title": "Ropinirole -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Orally administered ropinirole is rapidly absorbed and reaches peak plasma concentration in 1 to 2 hours. About 50% of the drug is metabolized on first-pass, and the absolute bioavailability ranges from 45% to 55%.\u00a0The drug reaches steady-state concentrations within\u00a02 days of initiating ropinirole. A high-fat diet may delay absorption, prolong the Tmax by 2.5 hours, and decrease the Cmax by 25%; ropinirole is better absorbed during fasting. Distribution: Ropinirole has a volume of distribution of 7.5 L/kg, and 40% of the drug is bound to plasma proteins.", "contents": "Ropinirole -- Mechanism of Action -- Pharmacokinetics. Absorption: Orally administered ropinirole is rapidly absorbed and reaches peak plasma concentration in 1 to 2 hours. About 50% of the drug is metabolized on first-pass, and the absolute bioavailability ranges from 45% to 55%.\u00a0The drug reaches steady-state concentrations within\u00a02 days of initiating ropinirole. A high-fat diet may delay absorption, prolong the Tmax by 2.5 hours, and decrease the Cmax by 25%; ropinirole is better absorbed during fasting. Distribution: Ropinirole has a volume of distribution of 7.5 L/kg, and 40% of the drug is bound to plasma proteins."}
{"id": "article-85736_7", "title": "Ropinirole -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: Most ropinirole is metabolized in the liver by N -despropylation and hydroxylation to form inactive metabolites. Cytochrome P450 1A2 is the primary enzyme involved in the metabolism of ropinirole. [2] [12] Elimination: The elimination half-life of the ropinirole immediate-release tablet is approximately 6 hours, and less than 10% of the orally administered drug is excreted unchanged in urine.", "contents": "Ropinirole -- Mechanism of Action -- Pharmacokinetics. Metabolism: Most ropinirole is metabolized in the liver by N -despropylation and hydroxylation to form inactive metabolites. Cytochrome P450 1A2 is the primary enzyme involved in the metabolism of ropinirole. [2] [12] Elimination: The elimination half-life of the ropinirole immediate-release tablet is approximately 6 hours, and less than 10% of the orally administered drug is excreted unchanged in urine."}
{"id": "article-85736_8", "title": "Ropinirole -- Administration -- Available Dosage Forms and Strengths", "content": "Two oral formulations are available as immediate-release tablets (0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, and 5 mg) and prolonged/extended-release tablets (2 mg, 4 mg, 6 mg, 8 mg, and 12 mg). The immediate-release form is administered\u00a03 times daily, while the extended-release is once-daily. [1] The therapeutic level for this drug is between 0.4 and 6\u00a0ng/mL; its use requires caution in older patients (older than 65) and women on hormonal replacement therapy (HRT) because of the slower clearance of the medication in these groups. [2] [13] In PD treatment, a dose\u00a0of 6\u00a0to 24 mg of the extended-release formulation is usually well-tolerated, and the clinician can individualize\u00a0dosing from patient to patient. [14]", "contents": "Ropinirole -- Administration -- Available Dosage Forms and Strengths. Two oral formulations are available as immediate-release tablets (0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, and 5 mg) and prolonged/extended-release tablets (2 mg, 4 mg, 6 mg, 8 mg, and 12 mg). The immediate-release form is administered\u00a03 times daily, while the extended-release is once-daily. [1] The therapeutic level for this drug is between 0.4 and 6\u00a0ng/mL; its use requires caution in older patients (older than 65) and women on hormonal replacement therapy (HRT) because of the slower clearance of the medication in these groups. [2] [13] In PD treatment, a dose\u00a0of 6\u00a0to 24 mg of the extended-release formulation is usually well-tolerated, and the clinician can individualize\u00a0dosing from patient to patient. [14]"}
{"id": "article-85736_9", "title": "Ropinirole -- Administration -- Parkinson Disease", "content": "Immediate-Release Tablets: The dose is titrated gradually every week in the following table.\u00a0If therapy with ropinirole is significantly interrupted, re-titration of the dose may be necessary.", "contents": "Ropinirole -- Administration -- Parkinson Disease. Immediate-Release Tablets: The dose is titrated gradually every week in the following table.\u00a0If therapy with ropinirole is significantly interrupted, re-titration of the dose may be necessary."}
{"id": "article-85736_10", "title": "Ropinirole -- Administration -- Parkinson Disease", "content": "Ropinirole tablets should be discontinued gradually and tapered over\u00a07 days in patients with PD according to the following method. First, the administration dose should be reduced from\u00a03 times daily to twice daily for the first\u00a04 days. For the 3 following days, dosing should be reduced to once-daily before cessation of ropinirole.", "contents": "Ropinirole -- Administration -- Parkinson Disease. Ropinirole tablets should be discontinued gradually and tapered over\u00a07 days in patients with PD according to the following method. First, the administration dose should be reduced from\u00a03 times daily to twice daily for the first\u00a04 days. For the 3 following days, dosing should be reduced to once-daily before cessation of ropinirole."}
{"id": "article-85736_11", "title": "Ropinirole -- Administration -- Parkinson Disease", "content": "Extended-Release Tablets: The initial dose is 2 mg, administered once-daily for\u00a02 weeks. Then, the dose may be increased by 2 mg weekly or at longer intervals based on the patient\u2019s response. The maximum dose is 24 mg administered daily.", "contents": "Ropinirole -- Administration -- Parkinson Disease. Extended-Release Tablets: The initial dose is 2 mg, administered once-daily for\u00a02 weeks. Then, the dose may be increased by 2 mg weekly or at longer intervals based on the patient\u2019s response. The maximum dose is 24 mg administered daily."}
{"id": "article-85736_12", "title": "Ropinirole -- Administration -- Restless Legs Syndrome", "content": "The recommended initial adult dose for RLS is 0.25 mg once-daily, about\u00a01 to\u00a03 hours before bedtime. A dose of 2 mg or less would suffice, and starting on a low dose is a good practice. In patients with RLS, ropinirole is usually started at a dose of 0.25 mg per day, incrementing 0.25 mg every\u00a02 to\u00a03 days until the reduction of symptoms. [15] After\u00a02 days, the dose can be increased to 0.5 mg once-daily (days 3 to 7) and 1 mg once-daily at the end of the first week of dosing to achieve optimal efficacy.", "contents": "Ropinirole -- Administration -- Restless Legs Syndrome. The recommended initial adult dose for RLS is 0.25 mg once-daily, about\u00a01 to\u00a03 hours before bedtime. A dose of 2 mg or less would suffice, and starting on a low dose is a good practice. In patients with RLS, ropinirole is usually started at a dose of 0.25 mg per day, incrementing 0.25 mg every\u00a02 to\u00a03 days until the reduction of symptoms. [15] After\u00a02 days, the dose can be increased to 0.5 mg once-daily (days 3 to 7) and 1 mg once-daily at the end of the first week of dosing to achieve optimal efficacy."}
{"id": "article-85736_13", "title": "Ropinirole -- Administration -- Restless Legs Syndrome", "content": "Dose titration after 1 week is as follows: week 2: 1 mg daily; week 3: 1.5 mg daily; week 4: 2.5 mg daily; week 5: 3 mg daily; week 6: 3.5 mg daily; week 7: 4 mg daily. This titration should be based on individual patient tolerability and therapeutic response to a maximum daily dose of 4 mg.\u00a0When discontinuing ropinirole treatment in patients with RLS, a gradual decrease of the daily dose is recommended.", "contents": "Ropinirole -- Administration -- Restless Legs Syndrome. Dose titration after 1 week is as follows: week 2: 1 mg daily; week 3: 1.5 mg daily; week 4: 2.5 mg daily; week 5: 3 mg daily; week 6: 3.5 mg daily; week 7: 4 mg daily. This titration should be based on individual patient tolerability and therapeutic response to a maximum daily dose of 4 mg.\u00a0When discontinuing ropinirole treatment in patients with RLS, a gradual decrease of the daily dose is recommended."}
{"id": "article-85736_14", "title": "Ropinirole -- Administration -- Specific Patient Populations", "content": "Hepatic impairment: Pharmacokinetic studies of ropinirole have not been conducted in patients with hepatic impairment.\u00a0Caution is advised as ropinirole is metabolized in the liver. [16]", "contents": "Ropinirole -- Administration -- Specific Patient Populations. Hepatic impairment: Pharmacokinetic studies of ropinirole have not been conducted in patients with hepatic impairment.\u00a0Caution is advised as ropinirole is metabolized in the liver. [16]"}
{"id": "article-85736_15", "title": "Ropinirole -- Administration -- Specific Patient Populations", "content": "Renal impairment: Dose adjustments are not required in patients with moderate renal impairment (CrCl of 30 to 50 mL/min). Patients with RLS and end-stage renal disease and on hemodialysis should be started on 0.25 mg once-daily. Further dose increments are based on the need for efficacy and tolerability. The recommended maximum daily dose is 3 mg in patients receiving regular dialysis. Supplemental doses after dialysis are not needed.", "contents": "Ropinirole -- Administration -- Specific Patient Populations. Renal impairment: Dose adjustments are not required in patients with moderate renal impairment (CrCl of 30 to 50 mL/min). Patients with RLS and end-stage renal disease and on hemodialysis should be started on 0.25 mg once-daily. Further dose increments are based on the need for efficacy and tolerability. The recommended maximum daily dose is 3 mg in patients receiving regular dialysis. Supplemental doses after dialysis are not needed."}
{"id": "article-85736_16", "title": "Ropinirole -- Administration -- Specific Patient Populations", "content": "Pregnancy considerations: If a patient using ropinirole intends to get pregnant or get pregnant, they should report to their clinician. Ropinirole is a pregnancy category C medicine. In addition, animal studies have reported teratogenic effects, so patients should be advised of this potential risk.", "contents": "Ropinirole -- Administration -- Specific Patient Populations. Pregnancy considerations: If a patient using ropinirole intends to get pregnant or get pregnant, they should report to their clinician. Ropinirole is a pregnancy category C medicine. In addition, animal studies have reported teratogenic effects, so patients should be advised of this potential risk."}
{"id": "article-85736_17", "title": "Ropinirole -- Administration -- Specific Patient Populations", "content": "Breastfeeding considerations: There is a lack of information on\u00a0ropinirole\u00a0use during breastfeeding. Since ropinirole suppresses serum prolactin, it can interfere with lactation. Alternative medicine is preferred while breastfeeding newborn or preterm infants. [17] Pediatric patients: The safety and efficacy of ropinirole have not been established in this population. Older patients: Increased adverse drug reactions such as hallucination, nausea, and vomiting\u00a0have been\u00a0reported. Dosage should be titrated slowly\u00a0based\u00a0on clinical response. [18]", "contents": "Ropinirole -- Administration -- Specific Patient Populations. Breastfeeding considerations: There is a lack of information on\u00a0ropinirole\u00a0use during breastfeeding. Since ropinirole suppresses serum prolactin, it can interfere with lactation. Alternative medicine is preferred while breastfeeding newborn or preterm infants. [17] Pediatric patients: The safety and efficacy of ropinirole have not been established in this population. Older patients: Increased adverse drug reactions such as hallucination, nausea, and vomiting\u00a0have been\u00a0reported. Dosage should be titrated slowly\u00a0based\u00a0on clinical response. [18]"}
{"id": "article-85736_18", "title": "Ropinirole -- Adverse Effects", "content": "Rare cases of hypersensitivity reactions, falling asleep during activities of daily living, somnolence (especially if concomitantly using CNS depressants), hallucinations, compulsive behaviors, augmentation, early morning rebound RLS, fibrotic complications, and retinal degeneration are also reported in clinical trials and postmarketing experience. Peripheral edema: Peripheral edema has been reported in\u00a0up to one-third of the patients on the extended-release form. [19]", "contents": "Ropinirole -- Adverse Effects. Rare cases of hypersensitivity reactions, falling asleep during activities of daily living, somnolence (especially if concomitantly using CNS depressants), hallucinations, compulsive behaviors, augmentation, early morning rebound RLS, fibrotic complications, and retinal degeneration are also reported in clinical trials and postmarketing experience. Peripheral edema: Peripheral edema has been reported in\u00a0up to one-third of the patients on the extended-release form. [19]"}
{"id": "article-85736_19", "title": "Ropinirole -- Adverse Effects", "content": "Anterocollis: The definition of this condition is the head positioned in flexion, resembling a \"drooping head,\" a rare side effect reported in a patient taking ropinirole. Discontinuation of the medication progressively reversed the symptoms within 4 months. [20]", "contents": "Ropinirole -- Adverse Effects. Anterocollis: The definition of this condition is the head positioned in flexion, resembling a \"drooping head,\" a rare side effect reported in a patient taking ropinirole. Discontinuation of the medication progressively reversed the symptoms within 4 months. [20]"}
{"id": "article-85736_20", "title": "Ropinirole -- Adverse Effects", "content": "Pisa syndrome: Cases of ropinirole-induced Pisa syndrome, referred to as \"pleurothotonus,\" have been recorded.\u00a0The condition is characterized by an abnormal lateral flexion of the trunk to the right or left. This condition occurred after a year on the medication and resolved 3 months after cessation of treatment. However, some reports maintain that Pisa syndrome is irreversible despite discontinuing this medication. [21] [22]", "contents": "Ropinirole -- Adverse Effects. Pisa syndrome: Cases of ropinirole-induced Pisa syndrome, referred to as \"pleurothotonus,\" have been recorded.\u00a0The condition is characterized by an abnormal lateral flexion of the trunk to the right or left. This condition occurred after a year on the medication and resolved 3 months after cessation of treatment. However, some reports maintain that Pisa syndrome is irreversible despite discontinuing this medication. [21] [22]"}
{"id": "article-85736_21", "title": "Ropinirole -- Adverse Effects", "content": "Reversible dyskinesias: Another movement disorder observed with ropinirole is severe reversible dyskinesias, which is very rare. This dose-dependent choreoform dyskinesia occurred in ropinirole monotherapy up to a dose of 15 mg daily but was also observed at a dose of 6 mg daily. [23] Dermal eruptions: Similar to other\u00a0D2 agonists, ropinirole rarely caused fixed dermal eruptions. This adverse effect is thought to be due to the inactivation of T cells. [24]", "contents": "Ropinirole -- Adverse Effects. Reversible dyskinesias: Another movement disorder observed with ropinirole is severe reversible dyskinesias, which is very rare. This dose-dependent choreoform dyskinesia occurred in ropinirole monotherapy up to a dose of 15 mg daily but was also observed at a dose of 6 mg daily. [23] Dermal eruptions: Similar to other\u00a0D2 agonists, ropinirole rarely caused fixed dermal eruptions. This adverse effect is thought to be due to the inactivation of T cells. [24]"}
{"id": "article-85736_22", "title": "Ropinirole -- Adverse Effects", "content": "Dopamine-agonist withdrawal syndroms: Withdrawal-emergent hyperpyrexia and confusion are reported in patients where ropinirole treatment is abruptly stopped or the dose is rapidly tapered down.\u00a0This condition resembles neuroleptic malignant syndrome without specific etiology. Withdrawal symptoms include insomnia, anxiety, apathy, depression, sweating, fatigue, and pain, which do not respond to treatment with levodopa. Recommendations include informing patients about the potential for withdrawal symptoms and monitoring symptoms during taper down and after treatment cessation. [25]", "contents": "Ropinirole -- Adverse Effects. Dopamine-agonist withdrawal syndroms: Withdrawal-emergent hyperpyrexia and confusion are reported in patients where ropinirole treatment is abruptly stopped or the dose is rapidly tapered down.\u00a0This condition resembles neuroleptic malignant syndrome without specific etiology. Withdrawal symptoms include insomnia, anxiety, apathy, depression, sweating, fatigue, and pain, which do not respond to treatment with levodopa. Recommendations include informing patients about the potential for withdrawal symptoms and monitoring symptoms during taper down and after treatment cessation. [25]"}
{"id": "article-85736_23", "title": "Ropinirole -- Adverse Effects", "content": "Impulse control disorders: Case reports of increased sexual drive, gambling, and binge eating have been reported. The\u00a0mechanism of action is thought to be the stimulation of dopamine D3 receptors by dopamine agonists.\u00a0Patients\u00a0have reported\u00a0an inability to control their urges. Patients may not convey problems to clinicians\u00a0due to embarrassment. In\u00a0severe\u00a0cases, clinicians should consider decreasing the dose of ropinirole; severe cases may require cessation of therapy. [26] [27] [28]", "contents": "Ropinirole -- Adverse Effects. Impulse control disorders: Case reports of increased sexual drive, gambling, and binge eating have been reported. The\u00a0mechanism of action is thought to be the stimulation of dopamine D3 receptors by dopamine agonists.\u00a0Patients\u00a0have reported\u00a0an inability to control their urges. Patients may not convey problems to clinicians\u00a0due to embarrassment. In\u00a0severe\u00a0cases, clinicians should consider decreasing the dose of ropinirole; severe cases may require cessation of therapy. [26] [27] [28]"}
{"id": "article-85736_24", "title": "Ropinirole -- Adverse Effects -- Drug-Drug Interactions", "content": "CYP1A2 enzyme is induced by omeprazole and smoking and can decrease the plasma concentration of ropinirole. CYP1A2 is inhibited by fluoroquinolones (eg, ciprofloxacin and norfloxacin), fluvoxamine, and mexiletine. The administration of these drugs may increase the plasma level of this drug. [12] Hormone replacement therapy (HRT, high dose estrogens) reduces the clearance of ropinirole; dose adjustment may be required when starting or stopping HRT.", "contents": "Ropinirole -- Adverse Effects -- Drug-Drug Interactions. CYP1A2 enzyme is induced by omeprazole and smoking and can decrease the plasma concentration of ropinirole. CYP1A2 is inhibited by fluoroquinolones (eg, ciprofloxacin and norfloxacin), fluvoxamine, and mexiletine. The administration of these drugs may increase the plasma level of this drug. [12] Hormone replacement therapy (HRT, high dose estrogens) reduces the clearance of ropinirole; dose adjustment may be required when starting or stopping HRT."}
{"id": "article-85736_25", "title": "Ropinirole -- Adverse Effects -- Drug-Drug Interactions", "content": "Dopamine antagonists\u00a0phenothiazines, thioxanthenes, butyrophenones, and metoclopramide can reduce the\u00a0efficacy of ropinirole. Concurrent administration of ropinirole and metoclopramide should be avoided. [29]", "contents": "Ropinirole -- Adverse Effects -- Drug-Drug Interactions. Dopamine antagonists\u00a0phenothiazines, thioxanthenes, butyrophenones, and metoclopramide can reduce the\u00a0efficacy of ropinirole. Concurrent administration of ropinirole and metoclopramide should be avoided. [29]"}
{"id": "article-85736_26", "title": "Ropinirole -- Adverse Effects -- Drug-Drug Interactions", "content": "As with most dopamine agonists, ropinirole's most frequently reported adverse effects\u00a0include nausea, vomiting, dyspepsia, abdominal pain, hallucinations, drowsiness, dizziness, leg edema, viral infection, syncope, orthostatic hypotension, and asthenic condition (ie, weakness, fatigue, and malaise). [11] [30] [31]", "contents": "Ropinirole -- Adverse Effects -- Drug-Drug Interactions. As with most dopamine agonists, ropinirole's most frequently reported adverse effects\u00a0include nausea, vomiting, dyspepsia, abdominal pain, hallucinations, drowsiness, dizziness, leg edema, viral infection, syncope, orthostatic hypotension, and asthenic condition (ie, weakness, fatigue, and malaise). [11] [30] [31]"}
{"id": "article-85736_27", "title": "Ropinirole -- Contraindications -- Warnings and Precautions", "content": "Clinicians should avoid using ropinirole in\u00a0patients who\u00a0abuse alcohol and patients with liver failure. [16] Ropinirole is contraindicated in patients who experience hypersensitivity reactions and anaphylaxis, including rash, pruritus, fixed drug eruptions, urticaria,\u00a0or angioedema to ropinirole or excipients. [24]", "contents": "Ropinirole -- Contraindications -- Warnings and Precautions. Clinicians should avoid using ropinirole in\u00a0patients who\u00a0abuse alcohol and patients with liver failure. [16] Ropinirole is contraindicated in patients who experience hypersensitivity reactions and anaphylaxis, including rash, pruritus, fixed drug eruptions, urticaria,\u00a0or angioedema to ropinirole or excipients. [24]"}
{"id": "article-85736_28", "title": "Ropinirole -- Monitoring", "content": "Patients initiating ropinirole therapy or escalating doses of ropinirole should be monitored for signs and symptoms of orthostatic hypotension.\u00a0Monitoring of UPDRS (Unified Parkinson disease rating scale) is\u00a0suggested\u00a0for monitoring the response to therapy. [6] Patients should be informed about the potential for withdrawal symptoms with ropinirole and monitor those signs and symptoms during and after discontinuation of ropinirole. [25]", "contents": "Ropinirole -- Monitoring. Patients initiating ropinirole therapy or escalating doses of ropinirole should be monitored for signs and symptoms of orthostatic hypotension.\u00a0Monitoring of UPDRS (Unified Parkinson disease rating scale) is\u00a0suggested\u00a0for monitoring the response to therapy. [6] Patients should be informed about the potential for withdrawal symptoms with ropinirole and monitor those signs and symptoms during and after discontinuation of ropinirole. [25]"}
{"id": "article-85736_29", "title": "Ropinirole -- Toxicity", "content": "Ropinirole can cause death\u00a0when taken with alcohol,\u00a0and persons who excessively consume alcohol should not use the drug. A lethal level up to\u00a06 times the therapeutic dose correlates with death. [13]", "contents": "Ropinirole -- Toxicity. Ropinirole can cause death\u00a0when taken with alcohol,\u00a0and persons who excessively consume alcohol should not use the drug. A lethal level up to\u00a06 times the therapeutic dose correlates with death. [13]"}
{"id": "article-85736_30", "title": "Ropinirole -- Toxicity", "content": "Patients with liver insufficiency require close monitoring; a case report of liver toxicity exists. The medication is metabolized\u00a0primarily in the liver, and the toxicity may be due to an immune reaction or a possible toxic metabolite. [1]", "contents": "Ropinirole -- Toxicity. Patients with liver insufficiency require close monitoring; a case report of liver toxicity exists. The medication is metabolized\u00a0primarily in the liver, and the toxicity may be due to an immune reaction or a possible toxic metabolite. [1]"}
{"id": "article-85736_31", "title": "Ropinirole -- Toxicity -- Signs and Symptoms of Overdose", "content": "Of these patients who used doses\u00a0exceeding 24 mg per day, commonly reported adverse reactions were related to its dopaminergic activity, ie, nausea, dizziness, hyperhidrosis, visual hallucinations, claustrophobia, palpitations, chorea, asthenia, and nightmares. Additional symptoms reported in overdose patients included vomiting, agitation, chest pain, increased coughing, fatigue,\u00a0orthostatic hypotension, syncope, dyskinesia, somnolence, and a confusional state. A recent study describes shock and arrhythmias as the probable\u00a0reason for mortality associated with ropinirole overdose. [32]", "contents": "Ropinirole -- Toxicity -- Signs and Symptoms of Overdose. Of these patients who used doses\u00a0exceeding 24 mg per day, commonly reported adverse reactions were related to its dopaminergic activity, ie, nausea, dizziness, hyperhidrosis, visual hallucinations, claustrophobia, palpitations, chorea, asthenia, and nightmares. Additional symptoms reported in overdose patients included vomiting, agitation, chest pain, increased coughing, fatigue,\u00a0orthostatic hypotension, syncope, dyskinesia, somnolence, and a confusional state. A recent study describes shock and arrhythmias as the probable\u00a0reason for mortality associated with ropinirole overdose. [32]"}
{"id": "article-85736_32", "title": "Ropinirole -- Toxicity -- Management of Overdose", "content": "There have been reports of patients who intentionally or\u00a0accidentally took more than the maximum recommended daily dose of ropinirole in clinical trials. General supportive measures are recommended, and vitals should be maintained when necessary. In clinical trials, the most significant overdose reported with ropinirole was 62 mg daily for\u00a07 days (total dose 435 mg).", "contents": "Ropinirole -- Toxicity -- Management of Overdose. There have been reports of patients who intentionally or\u00a0accidentally took more than the maximum recommended daily dose of ropinirole in clinical trials. General supportive measures are recommended, and vitals should be maintained when necessary. In clinical trials, the most significant overdose reported with ropinirole was 62 mg daily for\u00a07 days (total dose 435 mg)."}
{"id": "article-85736_33", "title": "Ropinirole -- Enhancing Healthcare Team Outcomes", "content": "Patients and caregivers should receive education about ropinirole, including its indications, adverse effects, signs of toxicity, and drug withdrawal. Compliance with medication can be extremely challenging, especially in PD, and the once-daily prolonged release of ropinirole greatly improves medication compliance. Additionally, the severity of motor symptoms, such as tremors and rigidity, may also be an important factor to consider to improve the compliance and management of these patients. [1] [11] [33] This is where an interprofessional team approach and consultation with a neurologist are most beneficial.", "contents": "Ropinirole -- Enhancing Healthcare Team Outcomes. Patients and caregivers should receive education about ropinirole, including its indications, adverse effects, signs of toxicity, and drug withdrawal. Compliance with medication can be extremely challenging, especially in PD, and the once-daily prolonged release of ropinirole greatly improves medication compliance. Additionally, the severity of motor symptoms, such as tremors and rigidity, may also be an important factor to consider to improve the compliance and management of these patients. [1] [11] [33] This is where an interprofessional team approach and consultation with a neurologist are most beneficial."}
{"id": "article-85736_34", "title": "Ropinirole -- Enhancing Healthcare Team Outcomes", "content": "Chronic RLS can be very challenging because of the sleep disruption for patients and family members. Ropinirole has demonstrated improved sleep quality, life, and mood in patients with RLS. [15] However, clinicians should try alternative treatments before using dopamine agonists like ropinirole. If ropinirole therapy is initiated, it should be started at a very low dose. This dosing approach is recommended because chronic use of dopamine agonists causes \u2018augmentation,\u201d which worsens symptoms and is often difficult to treat. [34] Sleep medicine specialist consultation may be necessary for refractory RLS cases.", "contents": "Ropinirole -- Enhancing Healthcare Team Outcomes. Chronic RLS can be very challenging because of the sleep disruption for patients and family members. Ropinirole has demonstrated improved sleep quality, life, and mood in patients with RLS. [15] However, clinicians should try alternative treatments before using dopamine agonists like ropinirole. If ropinirole therapy is initiated, it should be started at a very low dose. This dosing approach is recommended because chronic use of dopamine agonists causes \u2018augmentation,\u201d which worsens symptoms and is often difficult to treat. [34] Sleep medicine specialist consultation may be necessary for refractory RLS cases."}
{"id": "article-85736_35", "title": "Ropinirole -- Enhancing Healthcare Team Outcomes", "content": "When prescribing ropinirole, the prescriber should consult the pharmacist, verify\u00a0the appropriateness of therapy and the optimal starting dose, and check for potential drug-drug interactions. Nursing staff can monitor patient progress with the patient or caregivers, assess compliance, answer questions, and monitor for adverse events, reporting anything of concern to the clinician with recommendations for treatment modification. Emergency medicine teams, critical care physicians, and medical toxicologists play a crucial role in the overdose of ropinirole. A psychiatrist should be consulted once the patient is stable if the overdose is intentional.", "contents": "Ropinirole -- Enhancing Healthcare Team Outcomes. When prescribing ropinirole, the prescriber should consult the pharmacist, verify\u00a0the appropriateness of therapy and the optimal starting dose, and check for potential drug-drug interactions. Nursing staff can monitor patient progress with the patient or caregivers, assess compliance, answer questions, and monitor for adverse events, reporting anything of concern to the clinician with recommendations for treatment modification. Emergency medicine teams, critical care physicians, and medical toxicologists play a crucial role in the overdose of ropinirole. A psychiatrist should be consulted once the patient is stable if the overdose is intentional."}
{"id": "article-85736_36", "title": "Ropinirole -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Ropinirole -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}